# Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer

> **NCT00380588** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 84 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00380588
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2009-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00380588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00380588, "Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00380588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*